Volume 23 Issue 7
Jul.  2025
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2025  >  23(7): 1111-1114
WANG Yingying, YAN Dong, WANG Xin, REN Peipei, ZHANG Can, XUE Penghan, GAO Fei, ZENG Yanli. Clinical Efficacy and Short-Term Prognosis Analysis of DPMAS Combined with Half-Volume PE in the Treatment of Acute-on-Chronic Liver Failure[J]. Chinese Journal of General Practice, 2025, 23(7): 1111-1114. doi: 10.16766/j.cnki.issn.1674-4152.004076
Citation: WANG Yingying, YAN Dong, WANG Xin, REN Peipei, ZHANG Can, XUE Penghan, GAO Fei, ZENG Yanli. Clinical Efficacy and Short-Term Prognosis Analysis of DPMAS Combined with Half-Volume PE in the Treatment of Acute-on-Chronic Liver Failure[J]. Chinese Journal of General Practice, 2025, 23(7): 1111-1114. doi: 10.16766/j.cnki.issn.1674-4152.004076
shu

Clinical Efficacy and Short-Term Prognosis Analysis of DPMAS Combined with Half-Volume PE in the Treatment of Acute-on-Chronic Liver Failure

doi: 10.16766/j.cnki.issn.1674-4152.004076
  • 1.

    Department of Infectious Diseases, People' s Hospital of Zhengzhou University, Zhengzhou, Henan 450003, China

Funds:

 iGandanF-1082023-RGG003

 LHGJ20220078

 ZHKYQ202220

  • Received Date: 2024-09-05
    Available Online: 2025-10-25
    Abstract
  •   Objective   To explore the effects of plasma exchange (PE) and dual plasma molecular adsorption combined with half-volume plasma exchange (DPMAS combined with half-volume PE) on the improvement of clinical efficacy indices and short-term survival of the treatment of slow plus acute liver failure.   Methods   A total of 132 patients with acute-on-chronic liver failure, who were hospitalized at Henan Provincial People' s Hospital from January 2021 to July 2023, were selected. According to the treatment modality, patients were divided into the PE treatment group (83 cases) and the DPMAS combined with half-dose PE treatment group (49 cases). Laboratory parameters and mortality rates at 7 days, 28 days, and 90 days post-discharge were monitored in both groups before and after the different modes of artificial liver treatment.   Results   After treatment, the HB variation in the PE-treatment group demonstrated a significantly greater magnitude of change compared to the DPMAS combined with half-volume PE treatment group, with this differences attaining statistical significance (P < 0.05). Both treatment modalities improved liver function (P < 0.05), with the PE treatment group showing superior results in coagulation function compared to the DPMAS combined with half-dose PE group (P < 0.05). No statistically significant differences were observed in the comparison of bilirubin level changes and adverse reaction incidence rates between the two groups (P>0.05), but the cumulative 90-day mortality rate was significantly lower in the DPMAS combined with half-dose PE group (PE group: 31 cases, 37.3%; DPMAS combined with half-dose PE group: 10 cases, 20.4%), with statistical significance (P < 0.001).   Conclusion   The DPMAS combined with half-dose PE treatment is effective in improving liver function and significantly enhancing survival rates in patients with acute-on-chronic liver failure. Additionally, it addresses the issue of plasma resource shortages and markedly improves the prognosis for liver failure patients, providing more time for transitioning to liver transplantation.

     

    • FullText(HTML)
  • loading
    • References(17)
  • [1]
    康玮玮, 田辉, 冯丽丽, 等. 慢加急性肝衰竭患者长期生存状况变化及临床特点分析[J]. 肝脏, 2022, 27(5): 516-520.

    KANG W W, TIAN H, FENG L L, et al. Analysis on the long-term survival status and clinical characteristics of patients with acute-on-chronic liver failure[J]. Chinese Hepatology, 2022, 27(5): 516-520.
    [2]
    罗可, 刘波颖. 非生物型人工肝三种不同治疗模式在肝衰竭治疗中的研究进展[J]. 中国医药科学, 2024, 14(10): 30-33.

    LUO K, LIU B Y. Research progress of three different treatment modes of non-bioartificial liver in the treatment of liver failure[J]. China Medicine And Pharmacy, 2024, 14(10): 30-33.
    [3]
    LI Z W, TU S, YU X, et al. Hepatic and extrahepatic metabolic modulation in hbv-related decompensated cirrhosis and acute-on-chronic liver failure[J]. Virulence, 2024, 15(1): 2404953. DOI: 10.1080/21505594.2024.2404953.
    [4]
    李瑾, 李静, 柴梅, 等. DPMAS联合LPE与PE治疗乙型肝炎病毒相关早期肝衰竭的疗效对比和预后影响因素分析[J]. 临床和实验医学杂志, 2023, 22(3): 257-262.

    LI J, LI J, CHAI M, et al. Comparison and analysis of prognostic factors of DPMAS combination with LPE and PE in early HBV-associated liver failure[J]. Journal of Clinical and Experimental Medicine, 2023, 22(3): 257-262.
    [5]
    赵英妹, 聂红明, 张珏, 等. 肝硬化患者凝血五项的测定及其临床意义[J]. 诊断学理论与实践, 2021, 20(5): 480-483.

    ZHAO Y M, NIE H M, ZHANG J, et al. Detection of five coagulation indices in patients with cirrhosis and its clinical significance[J]. Journal of Diagnostics Concepts & Practice, 2021, 20(5): 480-483.
    [6]
    李海. 慢加急肝衰竭的诊断标准及管理[J]. 诊断学理论与实践, 2021, 20(5): 434-438.

    LI H. Diagnostic criteria and management of acute-on-chronic liver failure[J]. Journal of Diagnostics Concepts & Practice, 2021, 20(5): 434-438.
    [7]
    李建州, 李晓青, 杨英, 等. 适用于生物人工肝的3种不同肝细胞的增殖能力及代谢功能的比较研究[J]. 医学研究杂志, 2021, 50(8): 51-55.

    LI J Z, LI X Q, YANG Y, et al. Comparative study on the proliferation and metabolic functions of three different liver cell lines suitable for bioartificial liver[J]. Journal of Medical Research, 2021, 50(8): 51-55.
    [8]
    黄玥, 彭虹, 罗新华. 组合型人工肝的研究进展[J]. 临床肝胆病杂志, 2024, 40(2): 233-238.

    HUANG Y, PENG H, LUO X H. Research advances in combined artificial liver[J]. Journal of Clinical Hepatology, 2024, 40(2): 233-238.
    [9]
    中华医学会肝病学分会重型肝病与人工肝学组. 人工肝血液净化技术临床应用专家共识(2022年版)[J]. 实用肝脏病杂志, 2022, 25(3): 457-468.

    Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Expert consensus on clinical application of artificial liver and blood purification (2022 edition)[J]. Journal Of Practical Hepatology, 2022, 25(3): 457-468.
    [10]
    王璐, 许文雄, 彭亮. 组合型非生物型人工肝治疗成人慢加急性肝衰竭的研究进展[J]. 临床肝胆病杂志, 2022, 38(7): 1662-1666.

    WANG L, XU W X, PENG L. Research advances in combined non-bioartificial liver in treatment of acute-on-chronic liver failure in adults[J]. Journal of Clinical Hepatology, 2022, 38(7): 1662-1666.
    [11]
    秦维, 祝素平, 郑艳丽, 等. PE结合DPMAS对肝硬化并发慢加急性肝衰竭患者生存状况的影响[J]. 传染病信息, 2021, 34(2): 140-143, 147.

    QIN W, ZHU S P, ZHENG Y L, et al. Effect of PE combined with DPMAS on survival of patients with liver cirrhosis complicated with chronic and acute liver failure[J]. Infectious Disease Information, 2021, 34(2): 140-143, 147.
    [12]
    邹波, 朱龙川, 甘达凯, 等. 低置换量血浆置换术联合双重血浆分子吸附术治疗慢加急性肝衰竭患者短期预后的结果[J]. 实用医学杂志, 2024, 40(3): 348-352, 359.

    ZOU B, ZHU L C, GAN D K, et al. Effects of LPE combined with DPMAS on liver function and inflammatory cytokines in patients with acute?chronic liver failure[J]. The Journal of Practical Medicine, 2024, 40(3): 348-352, 359.
    [13]
    文苑, 祝娟娟. 双重血浆分子吸附系统序贯血浆置换联合连续性肾脏替代疗法治疗慢加急性肝衰竭合并急性肾损伤的效果分析[J]. 临床肝胆病杂志, 2024, 40(3): 556-561.

    WEN Y, ZHU J J. Clinical efficacy of double plasma molecular absorption system and sequential plasma exchange combined with continuous renal replacement therapy in treatment of acute-on-chronic liver failure with acute kidney injury[J]. Journal of Clinical Hepatology, 2024, 40(3): 556-561.
    [14]
    李新婷, 姚瑶, 郑嵘炅, 等. 血浆置换与双重血浆分子吸附联合半量血浆置换对肝衰竭治疗的疗效及短期生存率分析[J]. 中华肝脏病杂志, 2023, 31(7): 736-741.

    LI X T, YAO Y, ZHENG R Z, et al. Analysis of curative effect and short-term survival rate of plasma exchange and double plasma molecular adsorption combined with half-volume plasma exchange in the treatment of liver failure[J]. Chinese Journal of Hepatology, 2023, 31(7): 736-741.
    [15]
    陈茹茹, 罗厚江, 杨军, 等. 低分子量肝素联合新鲜冰冻血浆在危重新生儿凝血功能异常中的应用[J]. 中华全科医学, 2021, 19(4): 607-610. doi: 10.16766/j.cnki.issn.1674-4152.001873

    CHEN R R, LUO H J, YANG J, et al. Application of low molecular weight heparin combined with fresh frozen plasma in the treatment of coagulation abnormalities in critically ill neonates[J]. Chinese Journal of General Practice, 2021, 19(4): 607-610. doi: 10.16766/j.cnki.issn.1674-4152.001873
    [16]
    代梅, 申友书, 赵菲, 等. 血浆置换联合双重血浆吸附模式人工肝治疗对纤维蛋白原的影响[J]. 肝脏, 2023, 28(5): 523-526.

    DAI M, SHEN S Y, ZHAO F, et al. Effect of plasma replacement combined with dual plasma adsorption mode artificial liver therapy on fibrinogenJ]. Chinese Hepatology, 2023, 28(5): 523-526.
    [17]
    张露侃, 蒋素文, 胡爱荣. 组合型非生物人工肝支持系统治疗肝衰竭的研究进展[J]. 现代实用医学, 2023, 35(6): 834-837.

    ZHANG L K, JIANG S W, HU A R. Advances in the treatment of liver failure with a combined abiotic artificial liver support system[J]. Modern Practical Medicine, 2023, 35(6): 834-837.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (12) PDF downloads(0) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return